Presentation About Phase 3 Trial of DCVax-L for Glioblastoma To Be Made At New York Academy Of Sciences

BETHESDA, Md., May 4, 2024 /PRNewswire/ -- Northwest Biotherapeutics NWBO (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma will be made on May 10, 2024 at 11:10 a.m., by Dr. Linda Liau at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.

This presentation can be viewed virtually by registering online at the Academy's website at https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/summary

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an orphan disease.The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.